The outcome of the primary endpoint in the group treated with dapagliflozin+ GDMT was consistent among the predefined subgroups, including gender, race, age, hypertension, dyslipidemia, BMI, blood pressure values, heart rate, LDL cholesterol, use of beta-blockers, metformin, presence of established atherosclerotic disease (AMI, stroke, and CAD), use of renin-angiotensin-aldosterone system blockers (ACEI, ARB, or sacubitril-valsartan), LVEF, and GFR (Figure 5). The gene discussed is REN; the disease is Stroke.